KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities: 2017-2024

Historic Total Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $1.1 billion.

  • Amneal Pharmaceuticals' Total Current Liabilities fell 21.28% to $862.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $862.1 million, marking a year-over-year decrease of 21.28%. This contributed to the annual value of $1.1 billion for FY2024, which is 33.45% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Total Current Liabilities of $1.1 billion as of FY2024, which was up 33.45% from $846.6 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Current Liabilities peaked at $1.1 billion during FY2024, and registered a low of $676.9 million during FY2020.
  • In the last 3 years, Amneal Pharmaceuticals' Total Current Liabilities had a median value of $846.6 million in 2023 and averaged $909.7 million.
  • Data for Amneal Pharmaceuticals' Total Current Liabilities shows a peak YoY skyrocketed of 33.45% (in 2024) over the last 5 years.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Current Liabilities (Yearly) stood at $676.9 million in 2020, then increased by 0.05% to $677.2 million in 2021, then grew by 11.16% to $752.8 million in 2022, then grew by 12.46% to $846.6 million in 2023, then skyrocketed by 33.45% to $1.1 billion in 2024.